The anticancer effects of galangin are mostly due to its abilities to inhibit cell cycle progression, inhibiting mitogen-activated protein kinase (MAPK) (Liu et al., 2015), protein kinase B (Akt) (Li et al., 2018), or mammalian target of rapamycin (mTOR) activity thereby inducing apoptotic cell death by activating caspase-9/-8/-3 and inhibiting tumor invasion and metastasis by reducing the upregulation of matrix metalloproteinase-2/-9 (Kong et al., 2019; Wu et al., 2024). The gene discussed is AKT1; the disease is neoplasm.